Home 2024
Archives
Therapeutic potential of the endocannabinoid system to treat chronic pain in inflammatory disease
Pharma researchers Julie Blaising and Philip Smith from F. Hoffmann-La Roche Ltd. discuss the endocannabinoid system as a pathway to treat inflammatory diseases such as Inflammatory Bowel Disease (IBD) and endometriosis.
MAGL inhibition: A novel treatment option for combating inflammatory disease?
Pharma researchers Uwe Grether and Julie Blaising from F. Hoffmann-La Roche Ltd. highlight the vast therapeutic potential of MAGL inhibition for central and peripheral diseases.
CB₂R ligands to treat inflammatory diseases
Researchers discuss how scientific innovations might influence the discovery of future tailor-made CB2R-based anti-inflammatory treatments.
CB2R agonists in the clinics: A treasure chest for treating inflammatory diseases
Researchers give an update on clinical trials with CB2R agonists and their potential for the treatment of inflammatory diseases.
Visualizing the anti-inflammatory cannabinoid Type-2 receptor
Medicinal chemists describe how small molecule probes allow for the detection of CB2R, and thereby enable the discovery of novel anti-inflammatory treatments.
Challenges bringing CB₂R medicine to bedside
Drug hunters explain how to overcome pitfalls on the way to CB2R medicine and therapeutics.
Is CB₂R a hidden treasure trove for treating inflammatory diseases?
Expert scientists working on endocannabinoid system (ECS) trials explain how CB₂R can be used to treat inflammatory diseases.